Freeze-Dried Canine Plasma Advances Vet Blood Products

Veterinarian Kelly Mann describes canine freeze-dried plasma as one piece of a broader pursuit of shelf-stable whole blood analogs. His translational research aims to benefit both human and veterinary trauma care.

According to Mann, the pursuit of a shelf-stable whole blood analog is the primary direction for research. Canine freeze-dried plasma represents only a portion of this larger puzzle. He finds the potential for new patient therapeutic options exciting.

Research Informs Human and Veterinary Care

Mann states that advances in plasma lyophilization and novel blood products can inform human patient care. These efforts also drive the development of new veterinary blood products and therapeutic options. He supports rodent, porcine, and canine trauma research protocols because each informs and advances human patient care.

This work affords specific veterinary product development and availability for veterinary patient populations. Translational research efforts work to the benefit of both human and veterinary patients in this pursuit, Mann explains.

New Product Development Opportunities

The research and development route presents multiple opportunities for creating new veterinary blood products. Mann is excited that new form factors, like lyophilization of plasma, or the novel products themselves will lead to further innovations. These could spin off into synthetic cell production or even molecular mimetics of different blood components.

He emphasizes this is an exciting time due to the broad range of research occurring in this area. The information presented reflects the speaker's research and is not intended to recommend use outside the product's indication, according to an editor's note from dvm360.

Product Details and Safety

Mantel's canine freeze-dried plasma is intended for the treatment of hypovolemia and control of hemorrhage in dogs. The FDA determined that potential risks associated with the product are appropriately mitigated and does not intend to object to its marketing. The product should be reconstituted and administered according to its labeling.

As with other plasma products, transfusion reactions may occur. Kelly Mann is vice president of veterinary solutions at Mantel Technologies and a retired US Army Veterinary Corps officer. His work focuses on working-dog medicine and veterinary trauma research.